UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of the Clinical Trials Act on Noncommercial Clinical Research in Japan: An Interrupted Time-series Analysis

Journal of Epidemiology, 2022/01/05, Vol.32(1), pp.27-33

2022

Volltextzugriff (PDF)

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation

Cancer science, 2018-01, Vol.109 (1), p.182-192

2018

Volltextzugriff (PDF)

A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling

Nature cell biology, 2022-04, Vol.24 (4), p.565-578

2022

Volltextzugriff (PDF)

Primary Intramuscular Classic Hodgkin Lymphoma: A Rare Case Report

Internal Medicine, 2021/12/01, Vol.60(23), pp.3789-3793

2021

Volltextzugriff (PDF)

Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group

International journal of hematology, 2020-03, Vol.111 (3), p.401-408

2020

Volltextzugriff (PDF)

Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study

International journal of clinical oncology, 2019-11, Vol.24 (11), p.1449-1458

2019

Volltextzugriff (PDF)

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

Japanese journal of clinical oncology, 2022-01, Vol.52 (1), p.29-38

2022

Volltextzugriff (PDF)

Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission

Cancer science, 2020-08, Vol.111 (8), p.2923-2934

2020

Volltextzugriff (PDF)

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy

Japanese journal of clinical oncology, 2021-09, Vol.51 (9), p.1372-1382

2021

Volltextzugriff (PDF)

Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study

International journal of hematology, 2023-05, Vol.117 (5), p.694-705

2023

Volltextzugriff (PDF)

Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy

International journal of hematology, 2022-07, Vol.116 (1), p.89-101

2022

Volltextzugriff (PDF)

Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan

International journal of clinical oncology, 2012-12, Vol.17 (6), p.584-589

2012

Volltextzugriff (PDF)

Correction to: Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study

International journal of clinical oncology, 2020-04, Vol.25 (4), p.782-783

2020

Volltextzugriff (PDF)

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

International journal of clinical oncology, 2019-04, Vol.24 (4), p.445-453

2019

Volltextzugriff (PDF)

Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard‐dose azacitidine

Cancer reports, 2024-01, Vol.7 (1), p.e1938-n/a

2024

Volltextzugriff (PDF)

A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits

International journal of hematology, 2015-09, Vol.102 (3), p.304-311

2015

Volltextzugriff (PDF)

Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia

International journal of hematology, 2014-01, Vol.99 (1), p.41-52

2014

Volltextzugriff (PDF)

Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia

Med (New York, N.Y. : Online), 2024-08, Vol.5 (8), p.856-858

2024

Volltextzugriff (PDF)

HIV-associated Peripheral T-cell Lymphoma with a Cytotoxic Phenotype

Internal Medicine, 2014, Vol.53(18), pp.2127-2131

2014

Volltextzugriff (PDF)

Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy

International journal of clinical oncology, 2017-10, Vol.22 (5), p.972-979

2017

Volltextzugriff (PDF)

Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1

Blood, 2007-02, Vol.109 (3), p.1211-1219

2007

Volltextzugriff (PDF)

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia

International journal of hematology, 2011-05, Vol.93 (5), p.618-623

2011

Volltextzugriff (PDF)

Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale

SpringerPlus, 2016-05, Vol.5 (1), p.569-569, Article 569

2016

Volltextzugriff (PDF)

Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease

International journal of hematology, 2004-06, Vol.79 (5), p.420-433

2004

Volltextzugriff (PDF)

Diffuse Large B-Cell Lymphoma Carrying both t(3 ; 7)(q27 ; p12) and t(8 ; 14)(q24 ; q32)

Internal Medicine, 2011, Vol.50(8), pp.905-908

2011

Volltextzugriff (PDF)

1 – 25 von 202

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(169)
Mit Volltextzugriff
(171)

Publikationsform

Sprache

Englisch
(184)
Japanisch
(66)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Impact of the Clinical Trials Act on Noncommercial Clinical Research in Japan: An Interrupted Time-series Analysis

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation

A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling

Primary Intramuscular Classic Hodgkin Lymphoma: A Rare Case Report

Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group

Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy

Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study

Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy

Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan

Correction to: Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard‐dose azacitidine

A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits

Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia

Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia

HIV-associated Peripheral T-cell Lymphoma with a Cytotoxic Phenotype

Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy

Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia

Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale

Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease

Diffuse Large B-Cell Lymphoma Carrying both t(3 ; 7)(q27 ; p12) and t(8 ; 14)(q24 ; q32)

Suchergebnisse filtern